NCT05263609 2022-08-02
Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib
University of Oklahoma
Phase 2 Withdrawn
Clinical Trials
3 trialsNCT04197219 2020-11-05
Pembrolizumab With Axitinib in Recurrent Endometrial Cancer
Case Comprehensive Cancer Center
Phase 2 Withdrawn
NCT00386555 2012-08-09
A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.
Arog Pharmaceuticals, Inc.
Phase 2 Withdrawn